+

SE0301998D0 - Quil A fraction with low toxicity and use thereof - Google Patents

Quil A fraction with low toxicity and use thereof

Info

Publication number
SE0301998D0
SE0301998D0 SE0301998A SE0301998A SE0301998D0 SE 0301998 D0 SE0301998 D0 SE 0301998D0 SE 0301998 A SE0301998 A SE 0301998A SE 0301998 A SE0301998 A SE 0301998A SE 0301998 D0 SE0301998 D0 SE 0301998D0
Authority
SE
Sweden
Prior art keywords
quil
fraction
adjuvant
lps
derivatives
Prior art date
Application number
SE0301998A
Other languages
Swedish (sv)
Inventor
Bror Morein
Karin Loevgren Bengtsson
Jill Ekstroem
Katarina Ranlund
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Priority to SE0301998A priority Critical patent/SE0301998D0/en
Publication of SE0301998D0 publication Critical patent/SE0301998D0/en
Priority to DE602004023089T priority patent/DE602004023089D1/en
Priority to AU2004254152A priority patent/AU2004254152B2/en
Priority to AT04749076T priority patent/ATE442164T1/en
Priority to DK04749076T priority patent/DK1648505T3/en
Priority to CA2529363A priority patent/CA2529363C/en
Priority to EP04749076A priority patent/EP1648505B1/en
Priority to PCT/SE2004/001038 priority patent/WO2005002620A1/en
Priority to BRPI0412444A priority patent/BRPI0412444B8/en
Priority to JP2006518582A priority patent/JP4731475B2/en
Priority to PL04749076T priority patent/PL1648505T3/en
Priority to US10/562,866 priority patent/US8821881B2/en
Priority to ES04749076T priority patent/ES2331952T3/en
Priority to NZ544299A priority patent/NZ544299A/en
Priority to ZA200600151A priority patent/ZA200600151B/en
Priority to US14/445,690 priority patent/US20140335049A1/en
Priority to US14/714,664 priority patent/US20150320858A1/en
Priority to US15/054,801 priority patent/US20160184427A1/en
Priority to US15/874,262 priority patent/US20180369368A1/en
Priority to US16/701,948 priority patent/US20200345840A1/en
Priority to US17/477,739 priority patent/US20220241408A1/en
Priority to US18/376,666 priority patent/US12171828B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
SE0301998A 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof SE0301998D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (en) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof
NZ544299A NZ544299A (en) 2003-07-07 2004-07-07 Quil A fraction A for the enhancement of immune activities and immunomodulating activities
PL04749076T PL1648505T3 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
ES04749076T ES2331952T3 (en) 2003-07-07 2004-07-07 QUIL A FRACTION WITH LOW TOXICITY AND ITS USE.
AT04749076T ATE442164T1 (en) 2003-07-07 2004-07-07 QUIL A LOW TOXICITY FACTION AND THEIR USE
DK04749076T DK1648505T3 (en) 2003-07-07 2004-07-07 Low toxicity quil A fraction and its use
CA2529363A CA2529363C (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
EP04749076A EP1648505B1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
PCT/SE2004/001038 WO2005002620A1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
BRPI0412444A BRPI0412444B8 (en) 2003-07-07 2004-07-07 kilo fraction with low toxicity and its use
JP2006518582A JP4731475B2 (en) 2003-07-07 2004-07-07 QuilA fraction with low toxicity and use thereof
DE602004023089T DE602004023089D1 (en) 2003-07-07 2004-07-07 QUIL A FRACTION WITH LOW TOXICITY AND ITS USE
US10/562,866 US8821881B2 (en) 2003-07-07 2004-07-07 Quil A fraction with low toxicity and use thereof
AU2004254152A AU2004254152B2 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
ZA200600151A ZA200600151B (en) 2003-07-07 2006-01-06 Quil A fraction with low toxicity and use thereof
US14/445,690 US20140335049A1 (en) 2003-07-07 2014-07-29 Quil a fraction with low toxicity and use thereof
US14/714,664 US20150320858A1 (en) 2003-07-07 2015-05-18 Quil a fraction with low toxicity and use thereof
US15/054,801 US20160184427A1 (en) 2003-07-07 2016-02-26 Quil a fraction with low toxicity and use thereof
US15/874,262 US20180369368A1 (en) 2003-07-07 2018-01-18 Quil a fraction with low toxicity and use thereof
US16/701,948 US20200345840A1 (en) 2003-07-07 2019-12-03 Quil a fraction with low toxicity and use thereof
US17/477,739 US20220241408A1 (en) 2003-07-07 2021-09-17 Quil a fraction with low toxicity and use thereof
US18/376,666 US12171828B2 (en) 2003-07-07 2023-10-04 Quil A fraction with low toxicity and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (en) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof

Publications (1)

Publication Number Publication Date
SE0301998D0 true SE0301998D0 (en) 2003-07-07

Family

ID=27731119

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301998A SE0301998D0 (en) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof

Country Status (15)

Country Link
US (8) US8821881B2 (en)
EP (1) EP1648505B1 (en)
JP (1) JP4731475B2 (en)
AT (1) ATE442164T1 (en)
AU (1) AU2004254152B2 (en)
BR (1) BRPI0412444B8 (en)
CA (1) CA2529363C (en)
DE (1) DE602004023089D1 (en)
DK (1) DK1648505T3 (en)
ES (1) ES2331952T3 (en)
NZ (1) NZ544299A (en)
PL (1) PL1648505T3 (en)
SE (1) SE0301998D0 (en)
WO (1) WO2005002620A1 (en)
ZA (1) ZA200600151B (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2006078213A1 (en) * 2005-01-20 2006-07-27 Isconova Ab Vaccine composition comprisinga fibronectin binding protein or a fibronectin binding peptide
EP1764369A1 (en) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vaccines comprising truncated HBC core protein plus saponin-based adjuvant
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
EP1902727A1 (en) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vaccines comprising truncated HBC core protein plus saponin-based adjuvants
ES2630205T3 (en) 2006-11-20 2017-08-18 Duecom Use of lipid-containing particles comprising quillaja saponins for cancer treatment
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ621834A (en) 2008-06-27 2015-10-30 Zoetis Services Llc Novel adjuvant compositions
AU2010269148A1 (en) * 2009-07-10 2012-01-19 Isconova Ab New composition
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
ES2673957T5 (en) 2011-10-03 2021-12-15 Croda Int Plc Nanoparticles, procedure for the preparation and use of the same as carriers of amphipathic or hydrophobic molecules in the field of medicine, including cancer treatment, and food-type compounds
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
NZ630649A (en) 2012-03-22 2016-12-23 Janssen Vaccines & Prevention Bv Vaccine against rsv
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
EA030749B1 (en) 2013-03-08 2018-09-28 Янссен Вэксинс Энд Превеншн Б.В. Acellular pertussis vaccine
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
KR102236497B1 (en) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble prefusion rsv f polypeptides
BR112015029635B1 (en) 2013-05-30 2023-05-02 Janssen Vaccines & Prevention B.V FLU HEMAGGLUTININ STEM DOMAIN POLYPEPTIDE AND COMPOSITION
BR112015031509B1 (en) 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. RESPIRATORY SYNCYTIAL VIRUS (RSV) FUSION POLYPEPTIDE (F) RECOMBINANT PRE-FUSION AND COMPOSITION INCLUDING IT
US20160151479A1 (en) 2013-07-02 2016-06-02 Crucell Holland B.V. Method for preparing virosomes
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
CN109675029A (en) 2013-09-19 2019-04-26 硕腾服务有限责任公司 Oil-based adjuvants
DE102014005771A1 (en) 2014-04-23 2015-10-29 Clariant International Ltd. Use of aqueous drift-reducing compositions
SG11201610443WA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP6325751B2 (en) 2014-11-04 2018-05-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． HPV16 vaccine for treatment
CN115317600A (en) 2015-01-16 2022-11-11 硕腾服务有限责任公司 Foot and mouth disease vaccine
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EA035909B1 (en) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Stabilized soluble pre-fusion rsv f polypeptides
EA039065B1 (en) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Vaccine against rsv
CA2995740A1 (en) 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
JP6975709B2 (en) 2015-09-02 2021-12-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
CN114617959A (en) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 Vaccine compositions with improved stability and immunogenicity
KR20230035429A (en) 2015-12-23 2023-03-13 화이자 인코포레이티드 Rsv f protein mutants
MX2018012095A (en) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vaccine against rsv.
KR102506895B1 (en) 2016-04-05 2023-03-08 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble pre-fusion RSV F protein
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
DE102016207877A1 (en) 2016-05-09 2017-11-09 Clariant International Ltd Stabilizers for silicate paints
JP7046835B2 (en) 2016-05-12 2022-04-04 ヤンセン ファッシンズ アンド プリベンション ベーフェー Strong and balanced bidirectional promoter
DK3464331T3 (en) 2016-05-30 2021-01-18 Janssen Vaccines & Prevention Bv STABILIZED PREFUSION RSV F PROTEINS
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
CN109906411B (en) 2016-11-04 2022-12-27 卡博特公司 Nanocomposites containing crystalline polyesters and silicones
SG11201906271QA (en) 2017-02-09 2019-08-27 Janssen Vaccines & Prevention Bv Potent and short promoter for expression of heterologous genes
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. Methods and compositions for treating respiratory disease
CN111163800A (en) 2017-09-15 2020-05-15 扬森疫苗与预防公司 Methods for safely inducing immunity to RSV
PE20210651A1 (en) 2018-01-23 2021-03-26 Janssen Vaccines And Prevention B V VACCINES AGAINST FLU VIRUSES AND USES OF THEM
EP3768308A4 (en) 2018-03-19 2022-01-26 Novavax, Inc. Multivalent influenza nanoparticle vaccines
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
BR112020023846A2 (en) 2018-05-23 2021-04-13 Adc Therapeutics Sa MOLECULAR ADJUVANT
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
BR112021020907A2 (en) 2019-04-25 2022-04-19 Janssen Vaccines & Prevention Bv Recombinant influenza antigens
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CN113950333A (en) 2019-05-15 2022-01-18 扬森疫苗与预防公司 Prophylactic treatment of respiratory syncytial virus infection using adenovirus-based vaccines
EP4025247A1 (en) 2019-09-05 2022-07-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP4097122A4 (en) 2020-01-31 2024-07-17 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines
MX2022014161A (en) 2020-05-11 2022-12-02 Janssen Pharmaceuticals Inc Sars-cov-2 vaccines.
BR112022022942A2 (en) 2020-05-11 2022-12-13 Janssen Pharmaceuticals Inc RNA REPLICON ENCODING A STABILIZED CORONAVIRUS SPIKE PROTEIN
EP4150061A1 (en) 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
JP2023531554A (en) 2020-06-29 2023-07-24 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine Combinations Against Respiratory Syncytial Virus Infection
CN115916804A (en) 2020-07-06 2023-04-04 杨森制药公司 Stable coronavirus spike protein fusion proteins
JP2022060169A (en) 2020-10-02 2022-04-14 ファイザー・インク Cell culture process for RSVF protein production
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
CA3214415A1 (en) 2021-04-01 2022-10-06 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
EP4504252A2 (en) 2022-04-08 2025-02-12 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
IL316911A (en) 2022-05-12 2025-01-01 Msd Int Business Gmbh Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839376B2 (en) * 1978-10-30 1983-08-30 富士通株式会社 Ion implantation method
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
ES2039229T3 (en) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur PROCEDURE FOR THE PREPARATION OF IMMUNOGENIC COMPLEXES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPLEXES.
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (en) * 1996-02-21 1996-02-21 Bror Morein New use
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
PL1648505T3 (en) 2010-02-26
BRPI0412444A (en) 2006-09-19
ES2331952T3 (en) 2010-01-21
US20200345840A1 (en) 2020-11-05
NZ544299A (en) 2009-03-31
ATE442164T1 (en) 2009-09-15
US20140335049A1 (en) 2014-11-13
EP1648505B1 (en) 2009-09-09
US20220241408A1 (en) 2022-08-04
US20180369368A1 (en) 2018-12-27
AU2004254152A1 (en) 2005-01-13
DK1648505T3 (en) 2009-12-21
US8821881B2 (en) 2014-09-02
JP2007527386A (en) 2007-09-27
BRPI0412444B8 (en) 2021-05-25
US20060239963A1 (en) 2006-10-26
US20240024468A1 (en) 2024-01-25
DE602004023089D1 (en) 2009-10-22
JP4731475B2 (en) 2011-07-27
BRPI0412444B1 (en) 2016-06-14
AU2004254152B2 (en) 2009-10-29
US20150320858A1 (en) 2015-11-12
CA2529363A1 (en) 2005-01-13
ZA200600151B (en) 2007-01-31
US12171828B2 (en) 2024-12-24
EP1648505A1 (en) 2006-04-26
CA2529363C (en) 2013-04-02
WO2005002620A1 (en) 2005-01-13
US20160184427A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
SE0301998D0 (en) Quil A fraction with low toxicity and use thereof
MX393384B (en) SYNTHETIC GLUCOPYRANOSYL-LIPIDE ADJUVANTS.
BRPI0619795B8 (en) immunogenic composition, adjuvant composition, and, use of an immunogenic composition and an adjuvant
PT1187629E (en) ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE
MX2010001054A (en) Antigen-adjuvant compositions and methods.
WO2007109812A3 (en) Immunopotentiating compounds
UA94900C2 (en) Vaccine
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
BRPI0621181A8 (en) IMMUNOGENIC SUBSTANCES THAT COMPRISE AN ADJUVANT BASED ON POLYINOSINIC ACID - POLYCYTYDYLIC ACID
WO2006086449A3 (en) Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
MX2007003078A (en) Imidazoquinoline compounds.
NO20064781L (en) Methods and adjuvants to enhance immune responses to vaccines and methods of use
HK1132934A1 (en) Vaccine composition containing synthetic adjuvant
NO20070746L (en) Use of phosphated alkanols as dispersants, emulsifiers, hydrotropes, wetting agents and compatibility agents in agricultural compositions.
WO2006114680A3 (en) Vaccine adjuvants
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001035994A3 (en) Chitosan induced immunopotentiation
RU2002112709A (en) The method of presowing seed treatment
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载